Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy

To determine the safety of local palliative radiation therapy used in combination with anti-CTLA-4 immunotherapy.

Principal Investigator

Stanford Investigator(s)

CONTACT INFORMATION

Primary Contact:
Chuck Di Bari
(650) 498-4073